000210081 000__ 00878cam\a2200265\a\45e0
000210081 001__ 210081
000210081 005__ 20210513084910.0
000210081 008__ 981210s1998\\\\nyu\\\\\\b\\\\001\0\eng\\
000210081 010__ $$a   98004689
000210081 020__ $$a0789005638 (alk. paper)
000210081 035__ $$a(OCoLC)ocm38324279
000210081 035__ $$a210081
000210081 040__ $$aDLC$$cDLC$$dCOU
000210081 049__ $$aISEA
000210081 05000 $$aR726.8$$b.S37 1998
000210081 08200 $$a174/.28$$221
000210081 096__ $$aW 50$$bS385a 1998
000210081 1001_ $$aSchüklenk, Udo.
000210081 24510 $$aAccess to experimental drugs in terminal illness :$$bethical issues /$$cUdo Schüklenk.
000210081 260__ $$aNew York :$$bPharmaceutical Products Press,$$c1998.
000210081 300__ $$ax, 228 p. ;$$c23 cm.
000210081 504__ $$aIncludes bibliographical references (p. 205-217) and index.
000210081 650_0 $$aTerminal care$$xMoral and ethical aspects.
000210081 650_0 $$aDrugs$$xTesting$$xMoral and ethical aspects.
000210081 650_0 $$aHealth services accessibility.
000210081 85200 $$bgen$$hR726.8$$i.S37$$i1998
000210081 909CO $$ooai:library.usi.edu:210081$$pGLOBAL_SET
000210081 980__ $$aBIB
000210081 980__ $$aBOOK